Yes, the HPV vaccine can prevent cervical cancer. It blocks the high-risk HPV infections that, left alone for years, turn normal cervical cells into cancer. In a large Swedish study, girls vaccinated before 17 had an 88% lower risk of cervical cancer. It isn’t a complete shield, though, and that’s the part most people miss.
Dr. Sandeep Nayak, who provides the best cancer treatment in Bangalore sees the other side of this every week. “When a woman comes to me with cervical cancer, it started with a virus years ago, usually with no symptoms at all. The vaccine is for the daughters, ideally at 9 to 14. But the mother, the aunt, and the neighbor still need a Pap or HPV test. People hear ‘vaccine’ and think it’s finished. It isn’t. You need both.”
Wondering whether you or your daughter needs the vaccine, a screening test, or both?
How the HPV Vaccine and Cervical Cancer Prevention Fit Together?
It helps to know what the shot actually does, and what it leaves alone:
- Cervical cancer almost always starts with an infection that doesn’t go away. Most HPV infections clear on their own within a year or two. The ones that linger can quietly damage cervical cells for 10 to 20 years. The vaccine teaches the body to block the main cancer-causing types before that starts.
- The evidence is strongest for the young. The Swedish study followed about 1.7 million girls and women. Risk fell by 88% if the vaccine came before 17, and by about half if it came between 17 and 30. Younger girls are less likely to have been exposed, and the vaccine can’t treat an infection that’s already there.
- It covers the biggest culprits, not all of them. HPV types 16 and 18 are behind roughly 70 to 80% of cervical cancers in India. The rest come from other types, which is why screening can’t be skipped.
- India now offers it free, but only to a set group. Since Feb 28, 2026, government facilities give a single dose to girls aged 14. Girls outside that age, or already vaccinated, aren’t part of the drive, so parents of a 10-year-old or a 17-year-old will usually need the private route. Our cervical cancer treatment in Bangalore page explains what happens if cervical cancer is found.
Why Cervical Cancer Prevention Doesn’t End With the HPV Vaccine?
This is the part worth sharing with the women in your family:
-
- Screening still matters after vaccination. The WHO recommends an HPV test from age 30, repeated every 5 to 10 years. Where that’s not available, a Pap smear or visual test is used. Precancer rarely causes symptoms, so waiting for a warning sign means waiting too long.
- Missed the ideal age? You may still benefit. Women who are vaccinated later get less protection, but the Swedish data still showed about half the risk. Whether it’s worth it for you depends on your age and history, so ask your gynecologist. Cervavac, made by the Serum Institute, is available privately in India.
- The vaccine protects against more than cervical cancer, including throat, anal and other HPV-linked cancers, and boys can get it too. Our earlier post on HPV vaccine and cancer prevention covers that side.
- Don’t wait for a screening date if something’s off. Bleeding between periods, after sex or after menopause, unusual discharge, or ongoing pelvic pain deserve a gynecologist visit, vaccinated or not.
What Determines the Right Treatment Approach?
Choosing between PIPAC and HIPEC depends on the individual case, and the treating team reviews several things together.
The primary cancer. Colorectal, appendix, ovarian and stomach cancers that spread to the peritoneum behave differently, and each has its own evidence base.
How far the disease has spread. The extent of peritoneal involvement, often scored on imaging or at laparoscopy, shows whether the disease can be removed surgically.
Whether complete removal is possible. HIPEC is combined with cytoreductive surgery, so it generally suits patients whose visible disease can be removed. PIPAC is usually considered when that is not feasible.
Overall health and earlier treatment. Fitness for a long operation, organ function and previous chemotherapy all affect what is safe.
Response to chemotherapy so far. How the cancer has behaved on treatment helps guide the choice.
Review by the wider team. Surgical, medical and radiation oncology usually review the scans and records together before a plan is written.
Because these factors differ for each person, the choice is made case by case after reviewing the scans and records.
Key Takeaways
- PIPAC and HIPEC are two different ways of delivering chemotherapy inside the abdomen. Neither is right for everyone.
- HIPEC is combined with major surgery and suits patients whose disease can be removed. PIPAC is usually considered when that is not possible.
- The choice depends on the primary cancer, how far it has spread, overall health and earlier treatment.
- Scans and records are reviewed together by the treating team before a plan is made.
- For questions about your own case, you can contact the clinic at +91 9482202240.
FAQs
Can the HPV vaccine prevent cervical cancer completely?
Not completely. It lowers the risk sharply, but it doesn’t cover every cancer-causing type, and it can’t clear an infection you already have. That’s why screening stays important even after vaccination.
Do I still need a Pap smear or HPV test if I’ve had the vaccine?
Yes. Vaccinated women still need regular screening, usually starting around 30. Your gynecologist can tell you which test and how often.
Can I take the HPV vaccine if I’m already sexually active or over 26?
You may still benefit, though less than if you’d had it before any exposure. It won’t treat an existing infection. A gynecologist can help you decide whether it’s worth it for you.
Is the HPV vaccine safe?
Large safety reviews, including by the WHO, have found it safe. The usual effects are a sore arm, mild fever or dizziness, and serious reactions are rare.
Reference
- CDK4/6 Inhibitors vs Chemotherapy and Endocrine Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer, PubMed Central
- First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer With Liver Metastases, PubMed Central
- Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer, OncLive
- Breast Cancer Treatment in Bangalore, MACS Clinic
Disclaimer:
This content is published for educational and informational purposes only and is not a substitute for medical advice. Please consult your doctor before changing any treatment.